The Evolving Role of Chemotherapy and Other Systemic Therapies for Managing Localized Prostate Cancer-Reference-Cited by-同舟云学术

The Evolving Role of Chemotherapy and Other Systemic Therapies for Managing Localized Prostate Cancer

Published:2003-12 Issue:6S Volume:170 Page:
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

OH WILLIAM K.¹

Affiliation:

1. From the Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference51 articles.

1. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy;Kupelian;J Clin Oncol,2002

2. Nomograms as predictive models;Eastham;Semin Urol Oncol,2002

3. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer;D’Amico;JAMA,1998

4. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database;Stephenson;Urol Clin North Am,2002

5. Adjuvant and neoadjuvant therapy in prostate cancer;Chay;Semin Oncol,2001

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the management of high-risk localised and metastatic prostate cancer;BJU International;2012-01-19

2. Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer;The Prostate;2010-08-18

3. Morphologic Characterization of Preoperatively Treated Prostate Cancer: Toward a Post-Therapy Histologic Classification;European Urology;2010-06

4. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy;Cancer Chemotherapy and Pharmacology;2009-03-20

5. Chemotherapy for high-risk localized prostate cancer;BJU International;2006-04